Assuring Quality for Non-Hospital-Based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

Elaine Barfield, Robbyn Sockolow, Edward Hoffenberg, Shehzad Saeed, Sandra Kim, Leah Siebold, Joseph Picoraro, Jonathan Moses, Dana Dykes, Andrew Grossman, Ghassan Wahbeh, K. T. Park

Research output: Contribution to journalArticlepeer-review

Abstract

The primary aim of this Clinical Report by the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition is to provide formal guidance to pediatric gastroenterologists and clinicians, health systems, and insurance payers regarding home- and office-based infusions for biologic therapies in pediatric inflammatory bowel disease (IBD). Patients in North America are increasingly denied coverage by payers based on “place of service” codes at hospital-based infusion units where the treating clinicians primarily provide care. A task force with topic expertise generated 8 best practice recommendations to ensure quality of care for pediatric patients with IBD receiving non-hospital based biologic infusions. Pragmatic considerations discussed in this report include patient safety, pediatric-trained nurse availability, care coordination, patient-centeredness, shared liability, administrative support, clinical governance, and costs of care.

Original languageEnglish
Pages (from-to)680-686
Number of pages7
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume66
Issue number4
DOIs
StatePublished - Apr 1 2018

ASJC Scopus Subject Areas

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Keywords

  • biologics
  • Crohn disease
  • home infusions
  • home-based infusions
  • infliximab
  • ulcerative colitis
  • vedolizumab

Disciplines

  • Medical Specialties
  • Medicine and Health Sciences
  • Pediatrics

Cite this